What Helsinn Birex Pharmaceuticals does

Helsinn Birex Pharmaceuticals is the operating entity of Helsinn Group, a third-generation family-owned global pharmaceutical company founded in 1976 and headquartered in Lugano, Switzerland. The company develops, manufactures, and commercializes pharmaceutical products focused on supportive care, oncology, and dermato-oncology, with the stated objective of improving quality of life for patients with cancer and chronic diseases. Its commercial product portfolio comprises six core franchises: AKYNZEO (the first fixed-dose combination antiemetic combining an NK1 receptor antagonist with the 5-HT3 antagonist palonosetron for chemotherapy-induced nausea and vomiting), ALOXI/Onicit/Paloxi (palonosetron, a 5-HT3 antagonist used for 20+ years in CINV and postoperative nausea and vomiting), Valchlor/Ledaga (the first topical gel purposely developed for Mycosis Fungoides Cutaneous T-Cell Lymphoma), Adlumiz (anamorelin, the first and only product approved in Japan for cancer cachexia), Arokaris (fosnetupitant injectable for CINV in Japan), and Aulin/Mesulid/Nisulid (nimesulide NSAID available in 30+ countries but not the U.S.). Key technical differentiators include the proprietary fixed-combination formulation architecture underlying AKYNZEO, the optimized stable topical gel delivery system behind Valchlor/Ledaga, and the novel oral selective ghrelin receptor agonist mechanism of Adlumiz.

Helsinn operates a unique integrated licensing business model that spans the full product lifecycle — from internal development and regulatory affairs through manufacturing at its state-of-the-art plant in Dublin, Ireland (via Helsinn Birex Pharmaceuticals Ltd.) to global commercialization. The company combines direct commercial operations in the U.S. (Helsinn Therapeutics (U.S.), Inc., based in Iselin, NJ) and a presence in China (Helsinn Pharmaceuticals (Beijing) CO. Ltd.) with an extensive network of trusted distribution and licensing partners, enabling a commercial footprint in approximately 90 countries. Revenue mechanics combine direct product sales in controlled geographies with licensing royalties and supply/distribution income from regional partners (e.g., ESTEVE for German-speaking markets, MagnaPharm for Central and Eastern Europe). In January 2026, coinciding with its 50th anniversary, Helsinn underwent a major leadership reset, with Riccardo Braglia returning as CEO alongside a new executive team, and has since pursued geographic expansion, life-cycle product extensions (AKYNZEO Oral Suspension, ready-to-use vials, new formulations), and an AI-driven drug discovery collaboration with InVirtuoLabs to refresh its early-stage pipeline.

Pricing is not publicly disclosed, reflecting the company's private, family-controlled status (Braglia family ownership with no external institutional or private equity backers). End customers are healthcare providers, oncology centers, and hospital systems purchasing supportive care therapeutics across multiple regulatory jurisdictions. The company maintains compliance with GDPR, CCPA, and Swiss federal data protection regimes, reflecting its cross-jurisdictional operating model. Distribution scale spans 90 countries, with 251-500 employees and recent partnership-driven expansions in Austria and Central and Eastern Europe signaling continued geographic buildout of the AKYNZEO and ALOXI franchises.

Name

Helsinn Birex Pharmaceuticals

Legal name

Helsinn Healthcare S.A.

Website

https://helsinn.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

251–500 employees

Short description

Helsinn Birex Pharmaceuticals is a third-generation family-owned Swiss pharmaceutical company that develops, manufactures, and globally commercializes supportive care, oncology, and dermato-oncology products — including AKYNZEO, ALOXI, Valchlor, and Adlumiz — across 90+ countries via direct operations and an integrated licensing partner network.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Supportive Care and Oncology

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Supportive care pharmaceuticals
• Oncology supportive care
• Antiemetic drugs
• Specialty pharmaceutical manufacturing
• Pharmaceutical licensing partnerships

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Commercialization: Helsinn builds, manufactures, launches, and commercializes pharmaceutical products globally, focusing on supportive care, oncology and dermato-oncology. The company operates an integrated licensing business model.
2. Distribution and Supply: Manufacturing and supply chain operations from Ireland facility, distributing products through direct commercial operations and partner networks across 90+ countries.
3. Partnership Licensing: Distribution and licence agreements with partners like ESTEVE and MagnaPharm for regional commercialization of AKYNZEO and ALOXI products.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Helsinn is a global pharmaceutical company that develops, manufactures, launches, and commercializes specialty pharmaceutical products to improve the lives of patients with cancer and chronic diseases, with a focus on supportive care, oncology, and dermato-oncology. The company runs an integrated licensing business model covering the full product lifecycle and commercializes a portfolio of branded drugs including AKYNZEO (antiemetic), ALOXI (antiemetic), Valchlor/Ledaga (topical CTCL therapy), Adlumiz (cancer cachexia), Arokaris (CINV injectable), and Aulin/Mesulid/Nisulid (NSAID) across 90+ countries.

Product overview

Helsinn is a global pharmaceutical company operating an integrated licensing business model that builds, manufactures, launches, and commercializes products to improve quality of life for patients with cancer and chronic diseases. The product portfolio centers on supportive care, oncology, and dermato-oncology. Key products include: AKYNZEO® (fixed-dose combination antiemetic for CINV), ALOXI®/Onicit®/Paloxi® (5-HT3 antagonist for CINV and PONV), Valchlor®/Ledaga® (topical treatment for MF-CTCL), Adlumiz® (ghrelin receptor agonist for cancer cachexia in Japan), Arokaris® (fosnetupitant injectable for CINV in Japan), and Aulin®/Mesulid®/Nisulid® (NSAID for acute pain and dysmenorrhoea). The company has commercial presence in 90 countries with direct operations in the US and manufacturing in Ireland.

Differentiator

Problem solved

Functional benefit

Products and services

• AKYNZEO First and only fixed-combination antiemetic composed of an NK1 receptor antagonist (netupitant or fosnetupitant) and a 5-HT3 receptor antagonist (palonosetron). Approved for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly and moderately emetogenic chemotherapy.
• ALOXI / Onicit / Paloxi (Palonosetron) 5-HT3 receptor antagonist containing palonosetron, used for more than 20 years to prevent chemotherapy-induced nausea and vomiting (CINV) in adults and children aged 1 month and older, and also approved for postoperative nausea and vomiting (PONV).
• Valchlor / Ledaga (Topical Mechlorethamine Gel) Topical gel formulation of mechlorethamine (chlormethine), a bifunctional alkylating agent. First and only topical therapy purposely developed and indicated as first-line therapy to treat Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL); optimized, stable, non-greasy, quick-drying formulation for convenient at-home administration.
• Adlumiz (Anamorelin Hydrochloride) First and only product approved in Japan for cancer cachexia; contains anamorelin hydrochloride, a novel oral selective ghrelin receptor agonist approved for malignancy-associated weight loss and anorexia in non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.
• Arokaris (Fosnetupitant 235 mg Injectable) Fosnetupitant, a water-soluble phosphorylated prodrug of netupitant, used in combination with corticosteroids and 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting. Approved in Japan only.
• Aulin / Mesulid / Nisulid (Nimesulide NSAID) Nimesulide, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, approved for treatment of acute pain and primary dysmenorrhoea in adolescents and adults above 12 years old; available in more than 30 countries (not available in the USA).
• AKYNZEO New Formulation (EMA Submission) New AKYNZEO formulation submitted to the EMA in April 2025, expected to launch in H1 2026, intended to benefit cancer patients beyond the existing approved formulations.
• AKYNZEO Ready-to-Use Vial (U.S.) AKYNZEO injection in ready-to-use vial format in the U.S., designed for hospital and clinic use with no reconstitution or dilution required, no refrigeration, and compatibility with automated dispensing machines.

Quantifiable outcome

• AKYNZEO demonstrated 67% greater odds of complete response vs standard of care in MyRisk trial (81.0% vs 71.8%)
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered strategic and core.

• InVirtuoLabsstrategicStrategic or Co-development Partner · 25 February 2026Helsinn Healthcare and InVirtuoLabs signed a Strategic Collaboration in AI-Driven Drug Discovery. InVirtuoLabs, a Lugano-based drug discovery company specializing in AI-powered generative chemistry, will apply its generative chemistry platform InVirtuoGEN to design, optimize, and prioritize novel drug candidates using Helsinn's proprietary compound library.
• MagnaPharmcoreChannel Partner/ Reseller/ Distributor · 11 February 2026Helsinn and MagnaPharm entered a long-term Licence, Distribution and Supply Agreement for AKYNZEO and ALOXI in Poland, Romania, Czech Republic, Slovakia, and Hungary. MagnaPharm is a leading pharmaceutical group operating across Central & Eastern Europe, offering distribution, marketing, sales, pharmaceutical retail, market access, pricing and medical services.
• ESTEVEcoreChannel Partner/ Reseller/ Distributor · 9 February 2026Helsinn and ESTEVE expanded their Distribution and Licence Agreement for AKYNZEO and ALOXI to Austria. Both products are indicated for chemotherapy-induced nausea and vomiting (CINV) treatment in adult patients. The partnership, spanning over 15 years, previously covered Germany and is now strengthening presence in the German-speaking region while expanding patient access to supportive cancer care treatments.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• EUSA Pharma: European mid-size specialty pharmaceutical company focused on oncology and rare disease with a similar in-licensing/commercialization model, comparable therapeutic focus on supportive care, and a comparable geographic reach model.
• Norgine: European specialty pharmaceutical company that develops, manufactures, and commercializes branded prescription products across multiple therapeutic areas using a partner-driven commercialization model, mirroring Helsinn's integrated licensing approach.
• PharmaMar: Spanish specialty pharmaceutical company developing and commercializing branded oncology products, with a comparable therapeutic focus on oncology and supportive care and a similar European-mid-size pharma profile.

Broad incumbents

• Recordati: Italian-headquartered specialty pharmaceutical group with a broad branded portfolio across oncology, rare disease, and primary care, comparable in heritage (long-established family-influenced company) and European specialty focus to Helsinn.
• Menarini Group: Italian privately held pharmaceutical company with a broad branded portfolio spanning oncology, cardiology, and primary care, with similar Italian family-ownership heritage and European specialty pharma model to Helsinn.
• Ipsen: European mid-size specialty pharmaceutical group with a strong oncology and supportive-care focus, comparable in size, therapeutic emphasis, and geographic mix to Helsinn's oncology-supportive care franchise.
• Swedish Orphan Biovitrum (Sobi): European specialty pharmaceutical company focused on rare disease and specialty care, with comparable size, partner-driven commercialization, and emphasis on branded specialty therapeutics.
• Chiesi Farmaceutici: Italian privately held specialty pharmaceutical group with a branded portfolio spanning rare disease, specialty, and primary care; similar Italian family-ownership heritage and European specialty focus as Helsinn.
• Vifor Pharma: Swiss-headquartered specialty pharmaceutical company focused on branded specialty therapeutics, comparable in size, Swiss/EU base, and partner-driven commercialization model to Helsinn.

Regional players

• Kyowa Kirin: Japan-headquartered specialty pharmaceutical company with branded oncology and supportive-care assets (notably in cancer cachexia-adjacent areas), directly relevant as the home market for Adlumiz and Arokaris and as a potential global licensee partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/HelsinnGroup
• YouTubevimeo.com/helsinn
• LinkedInlinkedin.com/company/101863

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helsinn Birex Pharmaceuticals